Abu-Rgeef, Reeham, Australia

• Volume 36, No 5 (2023) - Original Articles
  Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience
  Abstract  PDF  HTML